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ovarian cancer and in an orthotopic model of pancreatic 
cancer.
Conclusions In animals, this clinical formulation and route 
of administration of Cantrixil demonstrated acceptable 
activity, safety pharmacology, genotoxicity and toxicology 
profile and constituted a successful Investigational New 
Drug application to the US Food and Drug Administration.
Keywords Chemo-resistant · Phenoxodiol · Cantrixil · 
Ovarian cancer · Flavonoids · Super-benzopyran
Introduction
With an age-standardised incidence of 9.4 women devel-
oping epithelial ovarian cancer (EOC) per 100,000 in the 
USA equating to 22,500 women developing the disease 
annually, approximately 14,200 of those women will die 
each year [1–3]. These statistics show that EOC accounts 
for the greatest number of deaths from all reported gynae-
cologic malignancies [4–7]. Early detection of the disease 
is critical for improved survival; however, due to non-spe-
cific symptomology and the lack of an effective screen-
ing marker with high sensitivity and specificity, many 
patients present at later stages of the disease (International 
Federation of Gynaecology and Obstetrics (FIGO) stage 
III) where the 10-year survival rate is poor (10–20%) [8]. 
Advances in therapeutic regimens employing traditional 
cytotoxic chemotherapy that utilise intraperitoneal deliv-
ery and dose-dense administration are improving response 
rates, as are targeted agents like bevacizumab, but these 
treatments fail to improve overall survival [9]. Moreover, 
patients often develop resistance to chemotherapy thought 
to be due to the presence of residual cancer stem cells in 
tumour niches, hence the urgent need to identify novel 
Abstract 
Purpose Recurrent, chemo-resistant ovarian cancer is 
thought to be due to a subgroup of slow-growing, drug-
resistant cancer cells with stem-like properties and a high 
capacity for tumour repair. Cantrixil targets this sub-popu-
lation of cells and is being developed as an intraperitoneal 
therapy to be used as first-line therapy in combination with 
carboplatin for epithelial ovarian cancer. The studies pre-
sented here justify further development.
Methods A GLP dog CV study using a 4 × 4 Latin Square 
Crossover study was conducted using telemetric ECG 
recordings from dogs post IP administration to assess for 
cardiac abnormalities. Mutagenic potential was assessed 
using the bacterial reverse mutation assay. Clastogenicity 
was assessed by determining micronuclei formation in the 
bone marrow of SPF Arc(S) Swiss mice dosed at clinical 
concentrations. TRX-E-002-1 toxicology was evaluated in 
GLP-compliant MTD and 28-day repeat-dose studies in 
rats and dogs.
Results In vitro TRX-E-002-1 has potent cytotoxic activ-
ity against human cancer cells including CD44+/MyD88+ 
ovarian cancer stem cells. TRX-E-002-1 increased phos-
phorylated c-Jun levels in these cancer cells resulting in 
caspase-mediated apoptosis. In vivo, Cantrixil was active in 
a model of disseminated ovarian cancer as a monotherapy 
and in combination with Cisplatin. Cantrixil was active as 
maintenance therapy in a model of drug-resistant, recurrent 
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therapeutics that target these slow-growing, highly drug-
resistant stem-like cancer cells.
Our lead drug candidate, TRX-E-002-1 (Fig. 1), is the 
active enantiomer of a super-benzopyran molecule that has 
been identified as having potent pan anti-cancer activity 
against a broad range of cancer phenotypes. It was selected 
particularly for its potent cytotoxicity against the two 
main sub-populations of ovarian cancer: chemo-resistant 
CD44+/MyD88+ ovarian cancer stem cell (OCSC) clones 
as well as in chemo-sensitive CD44−/MyD88− ovarian 
cancer cell (OCC) lines and potent activity in in vivo model 
of disseminated ovarian cancer.
Genesis of the super‑benzopyran drug class
Plant-derived phytochemicals include several broad classes 
of compounds including thiols (such as the isothiocy-
anates), terpenes (such as carotenoids and non-carotenoids) 
and phenols (including flavonoids and non-flavonoids). 
Epidemiological studies have shown that those countries 
with populations that consume diets high in phytochemicals 
typically have a lower incidence of cancer in the general 
population. Screening of phytochemicals against malignant 
cells have demonstrated that this family of molecules have 
broad pleiotropic anti-cancer effects that potentiate their 
ability at inhibiting cell proliferation, angiogenesis and, 
inducing mitotic arrest and apoptosis [10]. The anti-cancer 
properties of dietary phytochemicals may also be attrib-
utable to their epigenetic properties, including changes 
in DNA methylation patterns, histone modifications and 
miRNA expression levels [11]. Furthermore, phytochemi-
cals have been shown to modulate signalling pathways (i.e. 
Hedgehog, Wnt/β-catenin and Notch) in cancer stem cells 
which display enhanced DNA damage repair mechanisms, 
amplified anti-apoptotic activity, enhanced xenobiotic 
efflux and skewed production of certain pre-inflammatory 
cytokines [12].
Phytochemicals such as the flavonoid genistein are 
polyphenolic compounds found in plants characterised by 
a simple benzopyran structure. They are known to possess 
anti-tumour properties by inducing mitotic arrest and apop-
tosis. In addition, genistein can inhibit Notch signalling and 
mammosphere formation of breast cancer cells [13].
Medicinal chemists exploited the pan anti-cancer activ-
ity of the benzopyran pharmacophore found in genistein to 
develop the first anti-cancer drug candidate, phenoxodiol 
(idrinoxol) [14]. While demonstrating anti-cancer activity 
in animals in vivo as a monotherapy, the primary effect of 
phenoxodiol was its ability to enhance the cytotoxic effects 
of paclitaxel and cisplatin in taxane- and platinum-sensitive 
and -resistant cancer cells. Phenoxodiol was granted Inves-
tigational New Drug (IND) status by the US Food and Drug 
Administration (FDA) in February 2001 as an intravenous 
formulation and in June 2003 as an oral formulation. The 
intravenous formulation of phenoxodiol underwent three 
Phase I trials in multiple cancer types in Australia and in 
the USA [15]. Further developments in medicinal chemis-
try achieved progressively greater structural complexity of 
the simple benzopyran drug technology platform advanc-
ing from phenoxodiol, to triphendiol to NV-128 and then 
to ME-344, resulting in progressive log-fold increases in 
anti-cancer activity. Along with the increased potency came 
different mechanisms of cell death, with phenoxodiol caus-
ing caspase-dependent apoptosis via XIAP uncoupling, 
triphendiol causing both caspase-dependent and -independ-
ent apoptosis, and NV-128, NV-143 and ME-344 killing 
cancer cells by the uncoupling of mitochondrial oxidative 
phosphorylation resulting in catastrophic autophagy and 
caspase-independent apoptosis (see Fig. 2) [14, 16–18].
ME-143 (previously NV-143) was granted IND status 
for an intravenous formulation in August 2011 and has 
recently completed a Phase I trial [19]. An intravenous for-
mulation of ME-344 was granted IND status in May 2012. 
ME-344 has recently completed a Phase I first-in-man trial 
[20] and is about to commence an investigator-sponsored 
study of ME-344 in combination with the VEGF inhibitor 
bevacizumab (Avastin®) in HER2-negative breast cancer in 
2016 (MEI Pharma website).
Using Novogen’s proprietary Versatile Approach to 
Library-based Iterative Design (VAL-ID), we have cre-
ated a library of benzopyrans of even greater complexity 
through the addition of a range of chemical moieties that 
were previously technically impossible (termed super-ben-
zopyrans, SBPs). This strategy is based around the design, 
synthesis and evaluation of targeted small-molecule librar-
ies and has proven to be a rapid and robust method of iden-
tifying lead compounds. Several discrete sub-families of 
these SBPs have been identified on the basis of chemical 
Fig. 1  Chemical structure of TRX-E-002-1 (Cantrixil)
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composition, with up to thousands of potential analogues 
possible per patent sub-family. Without an initial target 
or docking studies, the discovery program has followed a 
ligand-based design strategy. This approach has allowed 
the generation of detailed structure activity relations 
(SAR’s) of the various SBP libraries. This allowed the defi-
nition of key structural requirements for enhanced activity, 
metabolic stability and pharmaceutical properties. We have 
created first- and second-generation drug candidates that 
exhibit significant activity against several types of cancer, 
including ovarian, both in vitro and in vivo. The latest drug 
discovery program has yielded a number of lead candidate 
compounds. The first of these compounds, TRX-E-002-1, 
is the subject of this review.
TRX‑E‑002‑1
Pharmacology
The chemical name of TRX-E-002-1 is (+) cis-4-(pa-
ra-hydroxyphenyl)-7,4′-dihydroxy-3′,5′-dimethoxy-
8-methylisoflavan (Fig. 1). The chemical formula is 
C24H24O6, and its molecular weight is 408.2. Synthesis of 
the active pharmaceutical ingredient yields a racemic mix-
ture of two enantiomers, the active enantiomer is termed 
TRX-E-002-1 and the inactive enantiomer is termed TRX-
E-002-2. The final step in the manufacture of TRX-E-002 
is a catalytic heterogenous hydrogenation. This reaction 
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Fig. 2  Mechanisms of cell death induced by benzopyran compounds 
by minor chemical modifications of the benzopyran scaffold. Minor 
modifications of the benzopyran scaffold alter the mechanisms of 
cell death. Phenoxodiol induces classic caspase-mediated apoptosis 
caused by inhibition of a surface NADH oxidase and disruption of the 
sphingomyelin cycle resulting in caspase-mediated apoptosis (path-
way 1); ME-128, NV-143 and ME-344 (previously NV-128) uncou-
ple mitochondrial oxidative phosphorylation resulting in autophagy 
mediated by increased AMP kinase due to changes in the ATP/ADP 
ratio and mTOR disruption and cell death induced by endonuclease 
G translocation to the nucleus that proceeds in the presence of a pan-
caspase inhibitor (pathway 2 and 3); triphendiol (NV-196) induces 
both caspase-mediated and caspase-independent cell death (pathways 
1 and 2). Mitochondrial respiratory chain complexes (I, II, III, and 
IV), along with complex V (ATP synthase), function together in mito-
chondrial oxidative phosphorylation and are shown in the inset
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stereoisomers around the core pyran ring. The two cis-oid 
stereoisomers are resolved into the two enantiomers via 
chiral chromatographic techniques. TRX-E-002-1 is the 
biologically active enantiomer and active ingredient of the 
drug product Cantrixil which is formulated in sulfobutyl-
ether β-cyclodextrin (Dexolve™).
Efficacy of TRX-E-002-1 has been demonstrated against 
a range of human cancer cell lines in vitro. TRX-E-002-1 
showed broad cytotoxic activity against ovarian, prostate 
and lung cancer cells, with IC50 values ≤0.1 μM. Activity 
in pancreatic and colorectal cancer cells and glioblastoma 
cells was more variable (Table 1).
Tumour recurrence post-chemotherapy is caused by 
the regrowth of the surviving innately drug-resistant can-
cer stem cells that remain in tumour niches during and 
post-chemotherapy. The expansion of this chemo-resistant 
cancer cell population, coupled with upregulation of pro-
survival pathways due to drug pressure, is thought to be 
responsible for the development of chemo-resistant recur-
rent disease [21]. Further, the inherent heterogeneity of 
ovarian tumours consists of epithelial cells with varying 
potential for stemness, and a population of cancer cells with 
varying mesenchymal status and invasiveness potential 
[22]. Therefore, to improve survival, a practical approach 
is the use of novel therapies that can induce cell death in 
these various subtypes of ovarian cancer cells. TRX-E-
002-1 was assessed against ovarian cancer stem cell line 
OCSC2, characterised by their expression of stem cell 
markers including CD44 and MyoD [22]. A major charac-
teristic of these cells is that they are drug resistant, able to 
form self-renewing spheroids in non-adherent culture, and 
recreate disseminated drug-resistant ovarian tumours that 
have a high degree of heterogeneity similar to the clinical 
profile observed in patients when inoculated into the peri-
toneal cavity of an immune-compromised mouse [22–24]. 
TRX-E-002-1 is able to induce cell death in chemo-resist-
ant CD44+/MyD88+ OCSC clones (Table 1) and chemo-
sensitive CD44−/MyD88− ovarian cancer cell lines when 
grown separately or in co-cultures which mimic tumour 
heterogeneity. We also demonstrated that TRX-E-002-1 
enhanced the effectiveness of cisplatin in co-culture studies 
and promoted the degradation of tumour spheroids.
In vivo, TRX-E-002-1, formulated in 20% SBECD, was 
active in a disseminated ovarian cancer model and a recur-
rent ovarian cancer model in which tumour recurrence is 
investigated following initial treatment of the OCSC2-inoc-
ulated mice with paclitaxel. In both models, TRX-E-002-1 
inhibited tumour growth following once daily intraperito-
neal administration.
In the disseminated ovarian cancer model, once daily 
intraperitoneal administration of 100 mg/kg racemic TRX-
E-002 or the active enantiomer TRX-E-002-1 in 20% 
SBECD for 13–14 days significantly inhibited tumour 
growth and reduced excised tumour weight at termination 
by 50–72%. In a dose-ranging study, the most effective 
dose regimen was 100 mg/kg compared with either a lower 
daily dose (50 mg/kg/day) or a higher dose administered 
intermittently (150 mg/kg 3 times weekly). All three regi-
mens were well tolerated.
In the recurrent ovarian cancer model, once daily intra-
peritoneal administration of 100 mg/kg TRX-E-002-1 in 
20% SBECD for 4 weeks inhibited tumour growth and 
reduced terminal tumour burden by 77%. Additionally, 
TRX-E-002-1 was more effective than paclitaxel adminis-
tered 12 mg/kg twice weekly.
The combination of TRX-E-002-1 and cisplatin was 
investigated in the murine model of disseminated ovarian 
cancer. Tumour growth during the 16-day treatment period 
was significantly inhibited by TRX-E-002-1 (100 mg/kg 
once daily), cisplatin (5 mg/kg once weekly) or TRX-E-
002-1 in combination with cisplatin. During the 5-week 
post-treatment period, tumour growth was decreased in 
both monotherapy groups, and to a significantly greater 
extent in the combination treatment group. By decreasing 
tumour growth kinetics in recurrent disease in this model, 
TRX-E-002-1 treatment resulted in lower tumour burden. 
Given that residual disease has been shown to directly cor-
relate with survival and is a prognostic factor in ovarian 
Table 1  Cytotoxic activity of TRX-E-002-1 in human cancer cell 
lines
a Concentration for 50% inhibition of cell growth (IC50) after incuba-
tion with TRX-E-002-1 for 72 h. Results are mean values ± standard 
error of mean (SEM) from duplicate experiments for, or from dupli-
cate wells on triplicate plates (n = 6)
b Duplicate experiments gave discrepant results, with respective IC50 
values of 0.067 and 7.37 μM
Cancer type Cell line IC50 (μM)
a
Ovarian SK-OV-3 0.028 ± 0.003
SK-OV-3 0.109 ± 0.026
JAM 0.065 ± 0.002
OVCAR-3 0.023 ± 0.006
Prostate DU145 0.041 ± 0.014
PC3 0.096 ± 0.077
C4-2B 0.014 ± 0.009
Lung A549 0.058
Pancreatic Panc-1 0.467 ± 0.378
ASPC1 0.227 ± 0.055
MiaPaCa2 3.72 ± 3.65b
Colorectal HT-29 1.765 ± 1.385
LOVO 0.084
LOVO 0.045 ± 0.005
Glioblastoma A172 0.051 ± 0.002
U87MG 0.205
U87MG 0.1 ± 0.07
307Cancer Chemother Pharmacol (2017) 79:303–314 
1 3
cancer, TRX-E-002-1 has the potential to increase survival 
by reducing the rate of recurrent disease [25].
Together, these data demonstrate that TRX-E-002-1 
is active against ovarian cancer stem cells and tumour 
spheres. It has the potential to prevent the formation of 
niche cancer stem cells within tumours that survive chemo-
therapy thereby preventing tumour recurrence. Cantrixil 
may enhance the effectiveness of standard-of-care cyto-
toxic therapeutics like cisplatin thereby enhancing overall 
survival benefits [25].
In a mouse model of pancreatic cancer (human Panc-1 
pancreatic tumour cells implanted orthotopically into 
female NOD-SCID mice), once daily intraperitoneal 
administration of TRX-E-002-1 100 mg/kg in 20% SBECD 
significantly reduced terminal pancreatic tumour burden 
(Fig. 3). These data provide in vivo evidence that TRX-E-
002-1 may have clinical application against other abdomi-
nal tumours.
The role of caspases and intracellular signalling path-
ways in the anticancer activity of TRX-E-002-1 was inves-
tigated in OCSC2 ovarian cancer stem cells. The activity 
of caspases 3/7 and 9 was markedly increased by treat-
ment with TRX-E-002-1. Activation of caspase 3/7 by 
TRX-E-002-1 was also demonstrated in cell lines repre-
sentative of colon, lung and brain cancer, indicating that 
TRX-E-002-1 is able to induce cell death across a range 
of cancer types (data not shown). Western blots showed 
decreased levels of inactive caspase 2 at both concentra-
tions of TRX-E-002-1, implying proteolytic conversion 
of this precursor to active caspase 2. TRX-E-002-1 also 
modulated phosphorylation of intracellular signalling mol-
ecules, with decreased levels of pERK (phosphorylated 
extracellular signal-regulated kinase) and increased levels 
of phosphorylated c-Jun (p–c-Jun). Activated p–c-Jun lev-
els increased progressively over the 24-h incubation period 
in response to both concentrations of TRX-E-002-1 tested. 
The results indicate that TRX-E-002-1-induced death of 
OCSC2 cells is associated with the phosphorylation/activa-
tion of c-Jun and down-regulation of pERK. Increased p–c-
Jun and decreased pERK levels were observed following 
incubation of OCSC2 cells after only 2-h’ exposure, indi-
cating these changes are one of the earliest effects of TRX-
E-002-1 treatment.
Further evidence for the role of c-Jun phosphorylation 
in the anti-tumour efficacy of TRX-E-002-1 comes from 
an experiment in OCSC2 cells incubated with the selective 
inhibitor of c-Jun N-terminal kinase, SP600125 [25]. West-
ern blotting confirmed that 10 μM SP600125 inhibited 
TRX-E-002-1-induced phosphorylation of c-Jun without 
affecting phosphorylation of ERK. SP600125 blocked the 
anti-tumour activity of 0.245 μM TRX-E-002-, indicating 
that the cytotoxic activity in OCSC2 cells is dependent on 
phosphorylation of c-Jun. Similar results were observed 
using SiRNA to knock down c-Jun [25].
Further studies are required to determine the initial trig-
ger of TRX-E-002-1 induced apoptosis. Our preliminary 
mechanism of action studies demonstrate that TRX-E-
002-1 is modulating both pro-survival and pro-death path-
ways resulting in caspase-mediated apoptosis (Fig. 4).
Safety pharmacology
Safety pharmacology studies have shown that TRX-E-
002-1 does not affect surface expression of wild-type 
human ether-à-go-go-related gene (hERG), indicating that 
it does not affect hERG trafficking. However, at concentra-
tions of 0.1-10 μM, the drug increased surface expression 
of the hERG single mutant (hERG-SM), identifying it as a 
potential blocker of hERG channel activity. A patch-clamp 
electrophysiological assay in hERG-transfected mam-
malian cells showed that TRX-E-002-1 concentration-
dependently inhibited hERG current with IC50 of 17.0 μM. 
Potential cardiovascular responses to intraperitoneal injec-
tion of TRX-E-002-1 were investigated in a GLP-compliant 
telemetry study in beagle dogs. Four male dogs received 
vehicle (20% SBECD) or TRX-E-002-1 (1, 10 or 30 mg/
Fig. 3  Efficacy of TRX-E-002-1 in an orthotopic model of pancre-
atic cancer. Female NOD-SCID mice were inoculated directly into 
the pancreas with PANC-1 human pancreatic epithelioid adenocarci-
noma cells transfected with luciferase gene. Tumours were allowed 
to establish prior to treatment initiation. Animals were dosed with 
TRX-E-002-1 100 mg/kg i.p. for 18 consecutive days over which 
time tumour growth was monitored using bioluminescent imaging. 
Following euthanasia at the predetermined end-point, tumours were 
excised and weighed. Final tumour (plus pancreas) weights excised at 
the terminal time point. *p < 0.001
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kg) on four separate occasions in a Latin Square design. 
Blood pressure, heart rate, ECG parameters and body 
temperatures were continuously recorded from 30 min 
before dosing until at least 24 h after each dose. Electro-
cardiographic (ECG) readings in dogs showed no effect of 
TRX-E-002-1 on the QTc interval following intraperitoneal 
administration at 1, 10 or 30 mg/kg. The dog study showed 
slight, transient increases in blood pressure and heart rate at 
10 and/or 30 mg/kg, but these effects were not considered 
adverse [26].
Pharmacokinetic drug–drug interactions
The potential for pharmacokinetic drug interactions result-
ing from inhibition of drug-metabolizing cytochrome P450 
enzymes was investigated in human hepatic microsomes 
in vitro. TRX-E-002-1 inhibited multiple cytochrome P450 
drug-metabolizing enzymes, including CYP2C9, CYP2C8, 
CYP2C19, CYP2B6, CYP3A4, CYP2D6, CYP2A6 and 
CYP1A2. IC50 values ranged from 1.5 to 75 μM (612–
30,600 ng/mL). Metabolism-dependent inhibition was 
observed for CYP2C8, CYP3A4 and CYP1A2. These 
results suggest that caution is warranted when adminis-
tering Cantrixil in combination with drugs metabolised 
by cytochrome P450 enzymes until further information is 
available. In particular, the potential interaction between 
Cantrixil and paclitaxel, a CYP2C9 substrate frequently 
used in the treatment of ovarian cancer, needs to be 
considered.
Potential induction of human drug-metaboliz-
ing cytochrome P450 enzymes by TRX-E-002-1 
was also investigated in human hepatocytes in vitro 
(VPT3079/2015). No evidence of CYP1A2 induction was 
observed. Equivocal evidence for induction of CYP2B6 
and CYP3A4 was seen in microsomes from one of three 
donors. Based on these results, TRX-E-002-1-mediated 
activation of pregnane X receptor (PXR, responsible for 
CYP3A4 induction) and/or constitutive androstane recep-
tor (CAR, responsible for CYP2B6 induction) cannot be 
excluded [26].
TRX‑E‑002‑1 pharmacokinetics
Absorption, distribution metabolism and excretion
The pharmacokinetics of TRX-E-002-1 was evaluated 
in male female Sprague–Dawley rats following a single 
intraperitoneal injection of 100 mg/kg TRX-E-002-1 in 
Fig. 4  Simple schematic over-
view of TRX-E-002-1-induced 
changes in signalling pathways 
known to influence cell prolif-
eration and death
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20% SBECD vehicle. Absorption was rapid, with Cmax 
mean plasma concentrations reached 0.25/1 h after dosing 
in female/male rats. Higher Cmax levels were observed in 
males. Mean plasma levels decreased to below the limit 
of quantification by 24 h (not shown). The AUC0−∞ value 
was 29,537 and 44,702 ng h/mL in female and male rats, 
respectively (Table 2). High tissue levels were observed 
0.5–6 h after dosing, with levels higher than the plasma 
concentration in pancreas, ovaries, large intestine, skin, 
kidneys, liver, stomach and adrenal glands (not shown). 
Treatment of plasma and tissue samples with glucuroni-
dase indicated the presence of low levels of a glucuronide 
conjugate of TRX-E-002-1 (not shown). Other metabolic 
pathways have not yet been investigated. Plasma elimina-
tion half-life was approximately 1.3 and 1.9 h. in female 
and male rats, respectively. Parent drug was excreted in the 
urine and faeces, and high levels of the glucuronide metab-
olite were found in the faeces.
Absorption of TRX-E-002-1 in beagle dogs was inves-
tigated following dosing on Day 1 of a 14-day pilot tox-
icity study. Plasma samples were collected and analysed 
following intraperitoneal administration of TRX-E-002-1 
at 10, 30 or 100 mg/kg. Absorption was rapid, with peak 
plasma concentration observed between 0.5 and 2 h. Mean 
Cmax values were roughly proportional to dose (626, 1935, 
6795 ng/mL at 10, 30 and 100 mg/kg, respectively). TRX-
E-002-1 was still detectable in most dogs 24 h after dos-
ing, and mean AUC0−last values were 4390, 8770 and 
58,500 ng h/mL, respectively. Plasma elimination half-life 
in individual animals ranged from 2.0 to 2.7 h, indepen-
dently of dose. Mean AUC0−∞ values were 4395, 11,300 
and 58,550 ng h/mL, respectively. Similar plasma phar-
macokinetic values were observed in a second study in 
which four dogs received a 10-mg/kg intraperitoneal dose 
of TRX-E-002-1. In the latter study, TRX-E-002-1 concen-
trations in gastrointestinal tissues 24 h after dosing were at 
least 30 times higher than those in plasma, with the highest 
concentrations being observed in the colon. However, by 
72 h, TRX-E-002-1 levels were close to or below the limit 
of quantification (Table 2).
TRX‑E‑002 ADME interspecies comparison
In female rats, plasma concentrations of unconjugated 
TRX-E-002-1 were approximately 90% of the total lev-
els (parent + glucuronide) up to 6 h after dosing, indicat-
ing that glucuronidation is a minor metabolic pathway 
in female rats. Tissue concentrations of total drug (par-
ent + glucuronide) were also similar to those in plasma 
except in liver, where they were 2–3 times higher.
In beagle dogs, plasma concentrations of unconjugated 
TRX-E-002-1 at early time points (1–4 h’ post-dose) were 
76–93% of the total levels (parent + glucuronide). At 8 h, 
the plasma concentrations of the glucuronide metabolites 
were similar to those of parent drug. By 24 h’ post-dose, 
the concentrations of TRX-E-002-1-glucuronide in plasma 
and gastrointestinal tissues (except colon) were 2–12 times 
higher than those of the parent drug. The increased levels 
of TRX-E-0021-glucuronide relative to those of parent 
drug at 24 h post-dose may reflect slower elimination of the 
glucuronide metabolites.
Dose proportionality has not been investigated in rats, 
but linear pharmacokinetics was observed in dogs. Elimi-
nation half-life appeared to be about 2.5 h in rats, and 2.2–
2.6 h in dogs.
Excretion
Excretion of TRX-E-002-1 was investigated in female 
Sprague–Dawley rats that received a single intraperitoneal 
injection of TRX-E-002-1 100 mg/kg in 20% SBECD. 
High levels of parent drug were measured in urine up to 
24 h after dosing and in faeces up to 48 h after dosing. The 
glucuronide conjugate, measured as the increase in TRX-E-
002-1 following treatment of the samples with beta-glucu-
ronidase, was found at levels similar to those of parent drug 
in faeces (rectal contents) up to 2 h after dosing, but was 
barely detectable in urine. Total amounts of parent drug and 
glucuronide excreted in faeces and urine were not calcu-
lated, so that the relative contributions of renal and biliary 
excretion pathways cannot be evaluated.
TRX‑E‑002‑1 toxicology
Cantrixil [TRX-E-002-1 formulated in sulfobutyl-
ether-beta-cyclodextrin (SBECD)] is being developed as 
an intraperitoneal therapeutic for abdominal cancers. All 
animal toxicity studies have therefore been completed 
using intraperitoneal administration. The pivotal repeat-
dose studies in rats and dogs were 28 days in duration; 
both were compliant with Good Laboratory Practice 
(GLP) regulations. Dose selection in the pivotal stud-
ies was supported by non-GLP single-dose and 14-day 
repeat-dose studies in both species. Non-GLP single-dose 
Table 2  Pharmacokinetics of TRX-E-002 in rat and dog plasma after 
IP injection
Parameter Rat (F) Dog (M + F) Dog (M + F)
Dose (mg/kg) 100 10 30 100 10
Tmax (h) 0.5 2.0 2.0 1.25 2
Cmax (ng/mL) 8355 626 1925 6795 425
T½ (h) ~2.5 2.6 2.5 2.2 2.6
AUClast (ng h/mL) 29,396 4390 8770 58,500 1630
AUC0−∞ (ng h/mL) 40,600 4395 11,300 58,550 1633
310 Cancer Chemother Pharmacol (2017) 79:303–314
1 3
intraperitoneal toxicity studies were conducted in rats 
and dogs as dose-ranging studies to determine the maxi-
mum tolerated dose. Toxicokinetic assessments were 
included in all four repeat-dose toxicity studies. In the 
two dose-ranging studies, plasma concentrations of TRX-
E-002-1 on Day 14 were determined. In Sprague–Dawley 
rats, Cantrixil was well tolerated following single intra-
peritoneal doses of 50 and 100 mg/kg, but deaths were 
observed at 150 mg/kg (females) and 200 mg/kg (both 
sexes). Test article-related clinical signs consisted of 
rough fur, stained fur, hunched posture, lethargy, swell-
ing of the abdomen, discoloured faeces, liquid faeces, 
soft faeces, reduced faeces and anogenital staining. Many 
of these signs were also observed at 100 mg/kg, and fae-
cal reduction was observed at all doses (≥12.5 mg/kg). 
Body weight gain was reduced at 150 and 200 mg/kg. As 
a single administration, the maximum tolerated dose was 
considered to be 50 mg/kg for both sexes. Based on these 
observations, 50 mg/kg/day was selected as the high dose 
for the 14-day repeat-dose intraperitoneal toxicity studies 
in rats.
In the rat 14-day pilot study, male and female SD rats 
were dosed once daily with intraperitoneal injections of 
vehicle (1:4 dilution of 20% SBECD in 0.9% saline) or 
TRX-E-002-1 (5, 15 or 50 mg/kg) for 14 days. Deaths 
were observed at 15 mg/kg/day (one female) and 50 mg/
kg/day (9/11 males and 8/11 females), and dosing of the 
remaining high-dose animals was terminated on Day 6. 
Clinical signs at all dose levels were reduced and/or liquid 
faeces, and staining of the fur of the forelimbs or around 
the eyes, nose and snout. Anogenital staining, rough fur, 
hunched posture, reduced activity and soft faeces were 
observed at 15 and/or 50 mg/kg/day. Body weight gain was 
dose-dependently reduced at doses ≥5 mg/kg/day in males 
and ≥15 mg/kg/day in females. Clinical laboratory assess-
ments at 5 and/or 15 mg/kg/day showed decreased eryth-
rocytic parameters, increased urea, and decreased albumin 
and total protein. Macroscopic pathology findings were 
limited to the 50 mg/kg/day group and included small tes-
tes, small thymus and small spleen. Organ weight analysis 
showed reduced weights of thymus, testes and ovaries at 
5 and/or 15 mg/kg/day. Treatment-related histopathologi-
cal changes were observed in testes (degeneration of sper-
matogenic elements lining the seminiferous tubules at all 
dose levels), adrenal glands (vacuolation of the zona fas-
ciculata at 15 and 50 mg/kg/day) and spleen (depletion of 
lymphocytes). Toxicokinetic results on Day 14 at the no-
observed-adverse-effect level (NOAEL) of 5 mg/kg/day 
were plasma Cmax was 909 and 257 ng/mL in males and 
females, respectively, and corresponding AUClast values of 
1870 and 665 ng h/mL.
In the rat GLP 28-day repeat-dose study, male and 
female SD rats were dosed once daily with intraperitoneal 
injections of vehicle (1:20 dilution of 20% SBECD in 
0.9% saline) or TRX-E-002-1 (0.5, 3 or 10 mg/kg) for up 
to 28 days. TRX-E-002-1 peak plasma concentrations were 
observed 0.25 – 0.5 h after dosing, except for mid-dose 
females on Day 1 (Tmax = 1 h). Estimated plasma elimi-
nation half-life was similar across sexes and doses ranging 
from 0.7 to 1.4 h on Day 1 and tended to be slightly pro-
longed at the mid- and high-doses on Day 28 (range = 0.9–
2.3 h). Mean plasma TRX-E-002-1 concentrations were 
roughly proportional to dose and were generally higher in 
males than in females. Cmax values for the 0.5, 3 and 10 mg/
kg doses on Day 1 were 35.4, 181 and 780 ng/mL, respec-
tively, in males, and 33.4, 150 and 535 ng/mL, respectively, 
in females. AUClast values on Day 28 tended to be higher 
than those on Day 1, except in low-dose males and high-
dose females (Table 2), indicating slight accumulation of 
TRX-E-002-1 with daily dosing.
No deaths were observed during the study. No clinical 
signs were observed at the low dose of 0.5 mg/kg/day. At 
3 mg/kg, reduced quantity of faeces was observed in both 
sexes during the first week of treatment. At 10 mg/kg, 
reduced quantity of faeces was observed during the first 1 
or 2 weeks in all animals. During the recovery period, fae-
ces were normal, although anogenital staining persisted up 
to 4 days after cessation of dosing in one high-dose male.
Body weight gain was reduced over Days 1–28 in high-
dose males, and during the first treatment week in mid-
dose males and high-dose females. Mean body weights at 
the end of the dosing period were 99.5, 95.7 and 89.2% of 
control values in males at 0.5, 3 and 10 mg/kg/day, respec-
tively; corresponding values in females were 99.8, 97.8 and 
97.8%, respectively. Mean body weight of the high-dose 
male group recovered to 93.6% of control value after the 
14-day recovery period. Food consumption was signifi-
cantly reduced throughout the dosing period in high-dose 
male and females, but was similar to control values during 
the recovery period. Ophthalmoscopy examination towards 
the end of the treatment period showed no treatment-related 
abnormalities.
Treatment-related macroscopic abnormalities at the ter-
minal necropsy were limited to distention of the caecum 
and/or colon in both sexes at 10 mg/kg/day, and obstruc-
tion of the colon in 3/10 males at this dose level. No mac-
roscopic findings were present after the recovery period. 
Organ weight analysis showed decreased absolute and rela-
tive testicular weights at 3 and 10 mg/kg/day (associated 
with decreased absolute epididymal weight at 10 mg/kg/
day), and decreased weights of salivary glands (absolute 
and relative to brain weight) in both sexes at 3 and 10 mg/
kg/day. Thymic weight was reduced in males at 3 and 
10 mg/kg/day and was increased in females at 10 mg/kg/
day. Testicular and epididymal weights were still reduced 
in the 10 mg/kg/day group after the recovery period.
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Serum biochemical assessments at the end of the 28-day 
treatment period showed slight (≤8%) decreases in total 
protein, albumin and globulin in males and females at 
10 mg/kg/day; these changes were statistically significant 
only for total protein and albumin in males. Similar changes 
were also seen after the 14-day recovery period (significant 
in males only). Haematological, coagulation and urinalysis 
assessments showed no treatment-related changes.
Histopathological examination showed treatment-related 
lesions in testes, epididymides and salivary glands. In 
the testes, degeneration of spermatogenic elements in the 
seminiferous tubules was observed with dose-dependent 
severity at 3 and 10 mg/kg/day. At 10 mg/kg/day, multifo-
cal degeneration was mild, and marked diffuse degenera-
tion was observed in two cases. Sperm degeneration was 
observed in the epididymides of all males in the same two 
dose groups, and was minimal to mild at 3 mg/kg/day, and 
moderate to marked at 10 mg/kg/day.
In summary, the major toxicity finding in rats dosed 
once daily for 28 days with TRX-E-002-1 was degenera-
tion of seminiferous tubules in the testes and of sperm in 
the epididymides at the high dose of 10 mg/kg/day. Other 
findings including transient faecal changes, reductions 
in weight gain and food consumption, serum biochemi-
cal changes, macroscopic lesions in the large intestine 
and atrophy of the salivary glands were considered non-
adverse. The NOAEL was considered to be 3 mg/kg/day in 
male rats and 10 mg/kg/day in females. The greater sen-
sitivity of male rats compared with females would appear 
to be associated with higher cumulative systemic exposure 
over the 28-day repeat-dose period.
For the acute dog MTD study, male and female beagle 
dogs were dosed with ascending doses of Cantrixil (10, 
20, 40, 80 and 200 mg/kg) as a single intraperitoneal injec-
tion. While no deaths were observed, treatment-related 
clinical signs at the highest dose were faecal changes 
(soft, liquid, mucoid, yellow discoloured, decreased), yel-
low emesis, thin appearance, lethargy and reduced activity. 
Body weight was not affected. Based on these observations 
100 mg/kg/day was selected as the high dose for the 14-day 
repeat-dose intraperitoneal toxicity studies in dogs.
For the dog 14-day pilot study, male and female beagle 
dogs were dosed once daily with intraperitoneal injections 
of vehicle (1:2 dilutions of 20% SBECD in 0.9% saline) 
or Cantrixil (10, 30 or 100 mg/kg) for 14 days. The doses 
were administered via an implanted catheter. Treatment-
related deaths were observed at 30 mg/kg/day (female on 
Day 11) and 100 mg/kg/day (both sexes, Day 5). Treat-
ment-related clinical signs at all dose levels included 
soft and liquid faeces, emesis and reduced activity. Body 
weights were decreased at 10 and 30 mg/kg/day. Nec-
ropsy findings in the animals that died included dark red 
discoloration in the gastrointestinal tract associated with 
microscopic finding of diffuse congestion of the submu-
cosa. Similar findings were observed in the TRX-E-002-
1-treated animals at the terminal sacrifice. Toxicokinetic 
measurements on Day 1 showed peak plasma concentra-
tions at 30–120 min after dosing. No gender differences 
were observed, and mean Cmax values for combined sexes 
were proportional to dose: 626, 1935 and 6795 ng/mL at 
10, 30 and 100 mg/kg/day, respectively. Mean AUClast val-
ues were also roughly proportional to dose: 4390, 8770 
and 58,500 ng h/mL, respectively. Plasma concentrations 
in surviving dogs on Day 14 were lower than those on Day 
1, with AUClast values of 1470 and 6270 ng h/mL at 10 and 
30 mg/kg/day, respectively. The NOAEL in this study was 
10 mg/kg/day.
For the dog GLP 28-day repeat-dose study, beagle 
dogs received intraperitoneal injections of vehicle (3:20 
dilution of 20% SBECD in 0.9% saline) or Cantrixil (1, 
10 or 30 mg/kg) three times per week for 4 weeks via an 
implanted catheter. Blood samples were collected from all 
dogs at 0.25, 0.5, 1, 2, 4 and 24 h after dosing on Days 1 
and 26. Peak plasma concentrations were observed 1–2 h 
after dosing, and group mean Tmax values ranged from 
1.0 to 1.8 h on Day 1, and from 1.2 to 1.5 h on Day 26. 
Estimated plasma elimination half-life was similar across 
sexes, doses and sampling days and ranged from 1.2 
to 2.6 h. Mean Cmax and AUClast values were similar in 
males and females and were greater than proportional to 
dose. Mean Cmax values in males/females on Day 1 were 
28.1/30.4, 497/453 and 1360/2060 ng/mL for the 1, 10 
and 30 mg/kg doses, respectively. Corresponding mean 
AUClast values on Day 1 were 71.4/80.5, 2810/2260 and 
10,500/11,000 ng h/mL, respectively, for males/females. 
Mean Cmax and AUClast values on Day 26 were similar to 
that on Day 1, indicating no accumulation of TRX-E-002-1 
with three times weekly dosing.
Treatment-related clinical signs observed in males and 
females at 10 or 30 mg/kg included emesis, and soft or 
liquid faeces. Mean body weight gain and food consump-
tion were slightly reduced in male dogs at 30 mg/kg. Food 
consumption was affected to a lesser extent in females at 
30 mg/kg and was not associated with discernible effect 
on body weight gain. Ophthalmological examination and 
electrocardiography and in Week 4 did not show treatment-
related abnormalities.
Haematological assessment showed slight but significant 
increases in total leucocyte in males and females at 10 and 
30 mg/kg, with a similar trend in males at 1 mg/kg. The dif-
ferential leucocyte count showed increased absolute num-
bers of neutrophils and monocytes. Similar changes were 
apparent but less severe in high-dose males and females 
after the 2-week recovery period. Coagulation parameters, 
serum chemistry, urinalysis and bone marrow examinations 
were unremarkable.
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Red discoloration in the caecum was also observed in 
all male dogs and one female dog in the 30 mg/kg group. 
Red discoloration in other parts of the intestinal tract was 
occasionally observed but did not appear to be treatment 
related. No treatment-related macroscopic abnormalities 
were observed after the recovery period. Organ weight 
analysis showed no treatment-related changes.
The most notable histopathological finding at the termi-
nal necropsy showed bilateral degeneration of spermato-
zoa in the epididymides at 30 mg/kg group, and multifocal 
degeneration of spermatids in the seminiferous tubules at 
10 and 30 mg/kg. After the 2-week recovery period, similar 
degenerative changes were observed in testes and epididy-
mides of one of the two dogs in the 30 mg/kg group.
In summary, the main toxicity findings following intra-
peritoneal administration of TRX-E-002-1 30 mg/kg in 
SBECD to beagle dogs three times per week for 4 weeks 
were emesis, soft and/or liquid faeces, leukocytosis with 
elevated neutrophil and monocyte counts, red discoloration 
in the caecum and degenerative changes in male reproduc-
tive organs. Some of these effects were also observed at the 
mid-dose of 10 mg/kg, while 1 mg/kg was a clear no-effect 
dose. Some of the effects at the mid-dose and high-dose 
were not considered adverse, and hence, the NOAEL was 
10 mg/kg in males and 30 mg/kg in females. No differences 
between sexes were apparent in toxic effects or systemic 
exposure, and the NOAEL for combined sexes was 10 mg/
kg. The 10 mg/kg dose was also considered the high-
est non-severely toxic dose (HNSTD), and mean plasma 
AUClast for combined sexes at this dose was 2310 ng h/mL 
on Day 26.
Degenerative changes in the testes and epididymides of 
male rats and dogs dosed with TRX-E-002-1 suggest that 
the drug may have an adverse effect on male fertility.
Genotoxicity
Genotoxicity testing of TRX-E-002-1 was performed in an 
ICH-compliant test battery (see ICH Guideline S2A), com-
prising an in vitro bacterial reverse mutation test, an in vitro 
mammalian cell mutation assay and an in vivo rodent bone 
marrow micronucleus assay. The assays were performed in 
compliance with GLP regulations.
The bacterial reverse mutation test employed Salmonella 
typhimurium strains TA1535, TA1537, TA98 and TA100, 
and Escherichia coli strain WP2uvrA in a conventional 
plate assay, with and without exogenous metabolic activa-
tion by a rat liver post-mitochondrial fraction (S9 mix). In 
both tests, all bacterial tester strains showed no significant 
increases in the number of revertant colonies in either the 
absence or presence of metabolic activation. Thus, TRX-
E-002-1 does not cause reverse gene mutations in bacteria 
under the conditions of the study.
The in vitro mammalian cell mutation assay utilised the 
forward mutation system at the thymidine kinase locus of 
the mouse lymphoma L5178Y cells using a microtitre clon-
ing technique. TRX-E-002-1 was tested in three experimen-
tal conditions: 3-h incubation at 37 °C with and without 
metabolic activation system (Aroclor-induced rat liver S9 
mix), and a 24-h incubation without metabolic activation 
(i.e. continuous treatment). Mutant frequencies for either 
colony size did not show statistically significant differences 
compared with the control values at any concentration in 
the absence of metabolic activation with either short-term 
treatment (3 h) or continuous treatment (24 h), or in either 
assay in the presence of metabolic activation for 3 h. Posi-
tive controls were methyl methanesulfonate in the absence 
of S9 and cyclophosphamide in the presence of S9 and 
gave the expected increases in mutant frequency assessed 
as either large or small colonies. Thus, TRX-E-002-1 does 
not cause forward gene mutation or chromosomal changes 
in mammalian cells under the conditions of the study.
The bone marrow micronucleus test was the in vivo 
part of the ICH genotoxicity testing battery and was con-
ducted in ARC(S) Swiss mice. Eight groups of mice (10/
sex/group) were given an intraperitoneal injection of vehi-
cle (20% w/v SBECD) or Cantrixil at 50, 200 or 400 mg/
kg and were killed 24 or 48 h later. Dimethyl-1,2 benzan-
thracene was used as the positive control. After prepara-
tion of the bone marrow cells, the number of micronucle-
ated polychromatic erythrocytes (PCEs) was determined in 
4000 PCEs per animal, and the proportion of PCEs in the 
total erythrocyte population in bone marrow was calculated 
from the examination of at least 500 erythrocytes as an 
index of bone marrow toxicity. The positive control group 
showed a statistically significant increase in the frequency 
of micronucleated PCEs and a reduction in the proportion 
of PCEs. The frequency of micronucleated PCEs was sig-
nificantly increased in female mice treated with TRX-E-
002-1 at 200 mg/kg (at 24 and 48 h) or 400 mg/kg (at 24 h). 
Slight increases in the frequency of micronucleated PCEs 
in male mice at 200 and 400 mg/kg were not statistically 
significant. The proportion of PCEs in the total erythro-
cyte population was decreased in both sexes at the 200 and 
400 mg/kg doses at both kill times. TRX-E-002-1 is there-
fore considered clastogenic in this system at the described 
concentrations in vivo [the equivalent 200/400 mg/kg dose 
in a rat is 16.2 mg/kg (600 mg/m2)/32.4 mg/kg (1200 mg/
m2) in a 60-kg human]. These data may imply some level 
of genotoxic risk for patients receiving TRX-E-002-1 at the 
equivalent dose in humans.
Carcinogenicity and reproductive toxicity studies of 
TRX-E-002-1 have not been completed. Carcinogenic-
ity studies are not warranted to support clinical trials or 
marketing of therapeutics intended to treat patients with 
advanced cancer.
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Discussion
The introduction of combination chemotherapy several 
decades ago has had little impact on ovarian cancer patient 
survival rates, where patients who initially respond to 
standard of care eventually relapse with recurrent disease 
presenting with chemo-resistant carcinomatosis. Research 
indicates that tumour recurrence is caused by the expan-
sion of chemo-resistant cancer stem cells that survive ini-
tial chemotherapy by residing in a niche microenviron-
ment within the tumour mass. It is this population of cells 
with modified pro-survival mechanisms, selected for by 
drug pressure of treatment that is thought to be responsi-
ble for the development of chemo-resistant recurrent dis-
ease. We describe the characterisation of TRX-E-002-1, a 
novel SBP molecule with significant potency against clini-
cally relevant models of ovarian cancer. TRX-E-002-1 was 
identified out of a medicinal chemistry-derived library of 
analogues with activity against a panel of cancer cells rep-
resentative of different malignancies and chemo-resistant 
OCSCs. TRX-E-002-1 anti-tumour activity was confirmed 
in vivo in a highly resistant ovarian cancer animal model 
in the treatment of primary disease, both as a monotherapy 
and in combination with cisplatin. Its utility as a mainte-
nance therapy was also demonstrated in a recurrent model 
of drug-resistant ovarian cancer by delaying disease recur-
rence. Differential survival rates exist between patients with 
no gross residual disease versus optimally resected residual 
disease [27]. Given the peritoneal cavity is the predominant 
site of disease in ovarian cancer, clinical researchers have 
employed intraperitoneal delivery of standard-of-care cyto-
toxics as a way to expose hypoxic, non-proliferating cells, 
which are resistant to chemotherapy, to higher concentra-
tions of the therapeutic for longer periods. Based on eight 
randomised clinical trials the NCI encourages the combina-
tion of IV and IP chemotherapy [28]. While the combin-
ing IV with IP regimens results in more toxicity compared 
with IV only, the benefits outweigh the risks with overall 
survival for women with advanced ovarian cancer being 
extended by about 1 year [29]. Women were less likely to 
die if they received an IP component to chemotherapy with 
a prolonged disease-free interval and a median survival 
advantage of 1 month in favour of the intraperitoneal arm 
compared with the IV arm [30]. We describe a complete 
pre-clinical study justifying the use of TRX-E-002-1 in 
ovarian cancer. It is being developed as an IP-administered 
therapeutics for abdominal cancers. The primary thera-
peutic indication is anticipated to be first-line therapy in 
combination with carboplatin for epithelial ovarian cancer. 
Safety pharmacology, genotoxicity and toxicology studies 
demonstrate that TRX-E-002-1 has an acceptable toxicity 
profile in rats and dogs, and is without genotoxicity and 
cardiotoxicity at clinically relevant concentrations.
Next steps
TRX-E-002-1 has recently achieved IND status.
A first-in-human, ascending-dose study to determine, 
safety, tolerability, pharmacokinetics and MTD of IP Can-
trixil will be conducted in women with refractory or recur-
rent ovarian cancer, fallopian tube cancer or primary peri-
toneal cancer. In an extension cohort of this study, patient 
will receive Cantrixil in combination with chemotherapy.
As part of this Phase I study, circulating tumours cells in 
whole blood harvested from patients pre- and post-treatment 
will be enumerated and assessed for clonogenic potential.
TRX-E-002-1 will be further assessed against a panel 
of ovarian cancer cells representative of the different ovar-
ian cancer subtypes to generate susceptibility profile. Bio-
marker studies are ongoing.
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